Lipton Allan
Division of Oncology, Room C6830, Hershey Medical Center, Hershey, PA 17033, USA.
Cancer Treat Rev. 2006;32 Suppl 1:20-2. doi: 10.1016/s0305-7372(06)80005-8.
Bone metastases, the most common metastatic manifestation of many cancers, including breast cancer and prostate cancer, contribute significantly to the pain and disability often associated with later stages of malignant disease. Although bisphosphonates have demonstrated efficacy in the treatment of metastatic bone disease (MBD), identifying patients most likely to develop bone metastases (and thus to benefit from treatment) is a challenge. In recent years, advances in understanding the pathophysiologic underpinnings of bone metastases have led to the discovery of several potential markers for dysregulation of bone coupling. Trials have been conducted to validate these biochemical markers and to explore their possible role in measuring efficacy of bisphosphonate treatment and of other metastatic bone therapies. In no area is this research more important than in the management of breast cancer. Although the value of these bone turnover markers is still unclear, and further research is necessary, results from these recent trials indicate some correlation.
骨转移是包括乳腺癌和前列腺癌在内的许多癌症最常见的转移表现，它在很大程度上导致了与恶性疾病晚期常常相关的疼痛和残疾。尽管双膦酸盐已被证明在治疗转移性骨病（MBD）方面有效，但识别最有可能发生骨转移（从而从治疗中获益）的患者是一项挑战。近年来，在理解骨转移病理生理基础方面取得的进展导致发现了几种骨耦联失调的潜在标志物。已经开展了试验来验证这些生化标志物，并探索它们在衡量双膦酸盐治疗及其他转移性骨治疗疗效方面的可能作用。在乳腺癌管理领域，这项研究最为重要。尽管这些骨转换标志物的价值仍不明确，还需要进一步研究，但这些近期试验的结果表明存在一定相关性。
